Matches in Wikidata for { <http://www.wikidata.org/entity/Q64123077> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- Q64123077 description "article scientifique publié en 2018" @default.
- Q64123077 description "artículu científicu espublizáu en xunetu de 2018" @default.
- Q64123077 description "im Juli 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q64123077 description "scientific article published on 27 July 2018" @default.
- Q64123077 description "wetenschappelijk artikel" @default.
- Q64123077 description "наукова стаття, опублікована в жовтні 2018" @default.
- Q64123077 name "Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407)" @default.
- Q64123077 name "Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study" @default.
- Q64123077 type Item @default.
- Q64123077 label "Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407)" @default.
- Q64123077 label "Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study" @default.
- Q64123077 prefLabel "Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407)" @default.
- Q64123077 prefLabel "Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study" @default.
- Q64123077 P1433 Q64123077-6058A222-C851-48E7-9967-34E28959FE8E @default.
- Q64123077 P1476 Q64123077-4A9BF6CF-1ECD-4B1C-9653-967DEBA5EAF8 @default.
- Q64123077 P2093 Q64123077-00FE2EAF-F312-4DD8-9487-FB6FDF7BC866 @default.
- Q64123077 P2093 Q64123077-10608AC5-EF66-4360-A4EF-8018518DD21A @default.
- Q64123077 P2093 Q64123077-1B400162-9071-4D20-AE2A-9BC163984377 @default.
- Q64123077 P2093 Q64123077-1FCECA5A-B0DA-4FB6-9F47-51C7D6C8BDDF @default.
- Q64123077 P2093 Q64123077-3927BB94-1FBA-463A-A844-C363F4A7D097 @default.
- Q64123077 P2093 Q64123077-3B066645-C6ED-4CDD-B5F3-74A12686C02C @default.
- Q64123077 P2093 Q64123077-4ACFBD5C-A2FC-4D72-AB8A-CF80CBF1A416 @default.
- Q64123077 P2093 Q64123077-6C128B2D-B521-404F-95BD-42B199C401E4 @default.
- Q64123077 P2093 Q64123077-75E4C917-9EEC-41E9-ADE2-75D9567FD813 @default.
- Q64123077 P2093 Q64123077-960DC56D-C63B-4C0D-AE05-7B42C769CC1A @default.
- Q64123077 P2093 Q64123077-B7F1DC72-D509-4473-B3B0-382718BD62ED @default.
- Q64123077 P2093 Q64123077-EBE3395F-BDD8-4D51-8C39-C7786C8A2B47 @default.
- Q64123077 P2093 Q64123077-EFB31614-D199-49EE-868E-F3E6B303D962 @default.
- Q64123077 P2093 Q64123077-F53E3C90-74B4-4FA3-9642-6B295905B007 @default.
- Q64123077 P304 Q64123077-4729E39D-2989-4350-92D6-EC97ECE5EC9F @default.
- Q64123077 P31 Q64123077-BE30E7BC-5CF9-4960-821E-D6E007151F84 @default.
- Q64123077 P356 Q64123077-08916C64-B003-48D6-8FC6-7AD7CE510C3A @default.
- Q64123077 P407 Q64123077-3D24318A-A280-4F52-A822-7D207F785DC1 @default.
- Q64123077 P433 Q64123077-6B124A42-3D0F-4700-9DAF-3E2C2333002F @default.
- Q64123077 P478 Q64123077-D1C22117-016F-4A7E-B97A-B3CD17EEC917 @default.
- Q64123077 P577 Q64123077-E439CA36-623D-4E8D-B015-08DFBE676102 @default.
- Q64123077 P698 Q64123077-0DFB3C68-4A80-4236-914F-E2EEA2DE67DD @default.
- Q64123077 P921 Q64123077-42E339CB-3F50-475A-8D64-C39C530B786F @default.
- Q64123077 P921 Q64123077-506BE033-B539-48CF-938E-54C3DB473F68 @default.
- Q64123077 P921 Q64123077-9DD87A90-FE25-41A4-80E3-FE18628B8ECC @default.
- Q64123077 P921 Q64123077-BAFFEAA1-90CE-4431-99A9-7C631154DFB9 @default.
- Q64123077 P356 J.PAN.2018.07.007 @default.
- Q64123077 P698 30075908 @default.
- Q64123077 P1433 Q15750271 @default.
- Q64123077 P1476 "Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407)" @default.
- Q64123077 P2093 "Akira Fukutomi" @default.
- Q64123077 P2093 "Haruhiko Fukuda" @default.
- Q64123077 P2093 "Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group" @default.
- Q64123077 P2093 "Hideki Ueno" @default.
- Q64123077 P2093 "Hiroshi Ishii" @default.
- Q64123077 P2093 "Hiroshi Katayama" @default.
- Q64123077 P2093 "Junji Furuse" @default.
- Q64123077 P2093 "Junki Mizusawa" @default.
- Q64123077 P2093 "Makoto Ueno" @default.
- Q64123077 P2093 "Masafumi Ikeda" @default.
- Q64123077 P2093 "Masato Ozaka" @default.
- Q64123077 P2093 "Nobumasa Mizuno" @default.
- Q64123077 P2093 "Takuji Okusaka" @default.
- Q64123077 P2093 "Tatsuya Ioka" @default.
- Q64123077 P304 "841-845" @default.
- Q64123077 P31 Q13442814 @default.
- Q64123077 P356 "10.1016/J.PAN.2018.07.007" @default.
- Q64123077 P407 Q1860 @default.
- Q64123077 P433 "7" @default.
- Q64123077 P478 "18" @default.
- Q64123077 P577 "2018-07-27T00:00:00Z" @default.
- Q64123077 P698 "30075908" @default.
- Q64123077 P921 Q12322152 @default.
- Q64123077 P921 Q17144959 @default.
- Q64123077 P921 Q212961 @default.
- Q64123077 P921 Q26852424 @default.